Lawrence K. Cohen

Somatix Therapy Corp. researches, develops, and commercialize proprietary processes for the genetic modification of cells and their use in the treatment of human disease. Somatix's assets include its highly efficient gene transfer technology, broad-based intellectual property, and focused product development programs. The company's most advanced clinical development program, the GVAX cancer vaccine, is in Phase I/II clinical trials for the treatment of metastatic renal cell carcinoma, advanced melanoma, and prostate cancer. It is located in Alameda, CA

Progenitor, Inc. is an American private company. The firm develops pharmaceutical compounds for nervous system. The company is headquartered in Columbus, OH.

VIA Pharmaceuticals, Inc. develops pharmaceutical products. It focuses on small-molecule drugs that target inflammation in the blood vessel wall as an innovative approach to treatment of cardiovascular disease. The company's strategy is to identify, acquire and develop compounds that intervene in the process of vascular inflammation, to reduce the incidence of major cardiovascular events and provide a significant clinical benefit to patients. It was founded in June, 2004 by Thomas Quertermous, Adeoye Y. Olukotun and Douglass B. Given. VIA is headquartered in San Francisco, CA.

Kadmon Holdings, Inc. is a biopharmaceutical company, which engages in discovering, developing, and commercializing small molecules and biologics to address unmet medical need. The company's clinical pipeline includes treatments for immune and fibrotic diseases as well as immuno-oncology therapies. The firms late-stage product candidate KD025, which is an orally administered selective inhibitor of Rho-associated coiled-coil kinase engages in development for the treatment of inflammatory and fibrotic diseases. The firm's a pivotal clinical trial of KD025 is underway in chronic graft-versus-host disease (cGVHD), as well as a Phase 2 clinical trial in systemic sclerosis. It is also developing next-generation immuno-oncology therapies, specifically IL-15 containing fusion proteins, for the treatment of cancer. The company's lead I-O product candidate, KD033, is an anti-PD-L1/IL-15 fusion protein. Kadmon was founded by Steven N. Gordon in September 2010 and is headquartered in New York, NY.

Zyomyx, Inc. manufactured point-of-care diagnostic devices based on cell-counting technology. It engaged in the development and commercialization of diagnostic platforms. The firm offered disposable CD4 T-cell, a point-of-care test for HIV and AIDS treatment. The company was founded by Peter Wagner, Steffen Nock, Christian Itin, and Dana Ault-Riche in 1998 and was headquartered in Fremont, CA.

First Mile Care, Inc. is a preventative chronic care company that offers a no-cost prevention program to help avoid type 2 diabetes. The company is based in Menlo Park, CA and was founded by Karl Ronn, who has been the CEO since incorporation. The company enables physicians to extend their medical practices and reduce prediabetes risks by providing affordable, scalable, and sustainable solutions. First Mile Care helps physicians, participants, and coaches work together to improve health outcomes and prevent type 2 diabetes. Physicians prescribe the proven prevention program, while Medicare covers the costs. First Mile Care provides the latest affordable, scalable, and sustainable resources for preventing chronic conditions such as prediabetes.

Part of American Medical Association, Health2047, Inc. is a healthcare transformation company based in Menlo Park, CA. The private company focuses on systemic transformation in the areas of data, chronic disease, and productivity to make healthcare more affordable, equitable, and with better outcomes. Health2047 invests in early-stage companies and provides a world-class network of entrepreneurs and mentors. Lawrence K. Cohen has been the CEO of the company since 2017.